Evidence map›Paper›PMID 24013380›Full record

ArticleInternational journal of molecular sciences2013

The role of initial oligomers in amyloid fibril formation by human stefin B.

Ajda Taler-Verčič, Tiina Kirsipuu, Merlin Friedemann, Andra Noormägi, Mira Polajnar, Julia Smirnova, Magda Tušek Znidarič, Matjaž Zganec, Miha Skarabot, Andrej Vilfan and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Amyloid Fibrils of Stefin B Show Anisotropic Properties.International journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Inhibition of Protein Aggregation by Several Antioxidants.Oxidative medicine and cellular longevity · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Ajda Taler-VerčičDepartment of Biochemistry, Molecular and Structural Biology, Jožef Stefan Institute, Ljubljana 1000, Slovenia. peep.palumaa@ttu.ee.
Tiina Kirsipuu
Merlin Friedemann
Andra Noormägi
Mira Polajnar
Julia Smirnova
Magda Tušek Znidarič
Matjaž Zganec
Miha Skarabot
Andrej Vilfan
Rosemary A Staniforth
Peep Palumaa
Eva Zerovnik
Jožef Stefan Institute · SITallinn University of Technology · EENational Institute of Biology · SIUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligomers are commonly observed intermediates at the initial stages of amyloid fibril formation. They are toxic to neurons and cause decrease in neural transmission and long-term potentiation. We describe an in vitro study of the initial steps in amyloid fibril formation by human stefin B, which proved to be a good model system. Due to relative stability of the initial oligomers of stefin B, electrospray ionization mass spectrometry (ESI MS) could be applied in addition to size exclusion chromatography (SEC). These two techniques enabled us to separate and detect distinguished oligomers from the monomers: dimers, trimers, tetramers, up to decamers. The amyloid fibril formation process was followed at different pH and temperatures, including such conditions where the process was slow enough to detect the initial oligomeric species at the very beginning of the lag phase and those at the end of the lag phase. Taking into account the results of the lower-order oligomers transformations early in the process, we were able to propose an improved model for the stefin B fibril formation.

Indexed as

AmyloidCystatin BHumansHydrogen-Ion ConcentrationProtein MultimerizationSpectrometry, Mass, Electrospray IonizationTemperatureAmyloidCystatin B

Identifiers

PMID24013380
PMCPMC3794784
OpenAlexW2130437419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.